Format

Send to

Choose Destination
Radiother Oncol. 2014 Dec;113(3):331-6. doi: 10.1016/j.radonc.2014.11.013. Epub 2014 Nov 22.

Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer.

Author information

1
Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Stefan.Koerber@med.uni-heidelberg.de.
2
Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: clara.schoneweg@t-online.de.
3
Institute of Biostatistics, German Cancer Research Center, Heidelberg, Germany. Electronic address: a.slynko@dkfz-heidelberg.de.
4
Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: David.Krug@med.uni-heidelberg.de.
5
Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Matthias.Haefner@med.uni-heidelberg.de.
6
Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Klaus.Herfarth@med.uni-heidelberg.de.
7
Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Juergen.Debus@med.uni-heidelberg.de.
8
Department of Radiation Oncology, University Hospital Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center Heidelberg, Germany. Electronic address: Florian.Sterzing@med.uni-heidelberg.de.
9
Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Germany. Electronic address: knebel@med.uni-heidelberg.de.
10
Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Germany. Electronic address: elena.prigge@med.uni-heidelberg.de.
11
Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Germany. Electronic address: miriam.reuschenbach@med.uni-heidelberg.de.

Abstract

BACKGROUND:

The purpose of this study was to evaluate HPV-DNA and p16(INK4a) (p16) expression as prognostic markers for outcome in patients with anal cancer.

METHODS:

From January 2000 to December 2011 a cohort of 105 anal cancer patients was treated with definitive chemoradiation at our institution. Tumor biopsies from 90 patients were analyzed for HPV-DNA by polymerase chain reaction and for p16 expression by immunohistochemistry.

RESULTS:

Median follow-up was 48.6months (range 2.8-169.1months). HPV-DNA or p16-expression was found in 75 anal cancers each (83.3%), concordance was detectable in 70 tumors (77.8%). Significantly improved overall survival (OS) [77.1% vs. 51.4%, p=0.005], progression-free survival (PFS) [64.0% vs. 35.0%, p<0.001] and improved local control [81.0% vs. 55.9%, p=0.023] was found for concomitant HPV- and p16-positive anal carcinomas (cHPPAC) in univariate analysis. Multivariate analysis showed better OS [p=0.015] and PFS [p=0.002] for cHPPAC.

CONCLUSION:

The combination of HPV-DNA and p16 can be used as an independent prognostic parameter in anal cancer patients.

KEYWORDS:

Anal [canal] cancer; HPV; Human papillomavirus; [Chemo] radiation; p16

PMID:
25465729
DOI:
10.1016/j.radonc.2014.11.013
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center